By Michael DabaieNuvalent Inc. shares were up 4.7%, to $13.25, and earlier traded as high as $14 as the clinical-stage biopharmaceutical company presented new data demonstrating expanded preclinical activity with lead programs NVL-520 and NVL-655. NVL-520 is being investigated in the Phase 1 portion of the Phase 1/2 ARROS-1 study for advanced ROS1-positive non-small-cell lung cancer and other solid tumors.

Source: Wall Street Journal April 09, 2022 03:12 UTC